Format

Send to

Choose Destination
Muscle Nerve. 2007 Oct;36(4):532-5.

Vitamin B(12) and methylmalonic acid levels in patients presenting with polyneuropathy.

Author information

1
Department of Neurology, Beth Israel Deaconess Medical Center, E/CC 810, Boston, MA 02215, USA. rnardin@bidmc.harvard.edu

Abstract

This study was designed to determine the prevalence of definite vitamin B(12) deficiency (defined as < or =240 pg/ml) and possible vitamin B(12) deficiency (defined as >240 pg/ml and a methylmalonic acid [MMA] level >243 nmol/L) in patients with polyneuropathy and to determine whether patients in both groups respond to vitamin B(12) repletion. We performed a retrospective cohort study of 581 patients presenting with polyneuropathy over a 2-year period; 4% had definite vitamin B(12) deficiency and 32% had possible deficiency as the sole or contributing cause for their polyneuropathy. For those who received treatment with vitamin B(12), subjective improvement was seen in 87% with definite and in 43% with possible deficiency. Possible vitamin B(12) deficiency, defined as an elevated MMA level, is a common finding in patients with polyneuropathy and treatment of these patients with vitamin B(12) may lead to clinical improvement.

PMID:
17623858
DOI:
10.1002/mus.20845
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center